Your browser doesn't support javascript.
loading
Sclerostin: Another vascular calcification inhibitor?
Claes, Kathleen J; Viaene, Liesbeth; Heye, Sam; Meijers, Björn; d'Haese, Patrick; Evenepoel, Pieter.
Afiliação
  • Claes KJ; Department of Nephrology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. kathleen.claes@uzleuven.be
J Clin Endocrinol Metab ; 98(8): 3221-8, 2013 Aug.
Article em En | MEDLINE | ID: mdl-23788689
ABSTRACT
CONTEXT Sclerostin, a Wnt antagonist produced by osteocytes, regulates osteoblast activity and is a well-established key player in bone turnover. Recent data indicate that the Wnt pathway may also be involved in vascular calcification.

OBJECTIVE:

The present study tests the hypothesis that serum sclerostin levels are associated with vascular calcification in patients with chronic kidney disease (CKD) not yet receiving dialysis. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS We performed a cross-sectional analysis in 154 patients with CKD. Aortic calcification (AC) was assessed by lumbar X-ray and scored with a maximum score of 24. In addition to traditional and nontraditional cardiovascular (CV) risk factors, serum sclerostin levels were assessed (ELISA). Regression analysis was performed to identify determinants of serum sclerostin and AC.

RESULTS:

AC was present in 59% of patients. Older age (P < .0001), male sex (P = .006), lower estimated glomerular rate (eGFR) (P = .0008), lower bone-specific alkaline phosphatase (P = .03), and the absence of AC (P = .006) were identified as independent determinants of higher serum sclerostin levels. In univariate logistic regression, higher age, diabetes, CV history, higher body mass index, higher serum C-reactive protein and sclerostin levels and lower estimated glomerular rate were all associated with the presence of AC. In multivariate analysis, lower, not higher, sclerostin levels (P = .04, odds ratio [OR] per ng/mL of 0.24), higher age (P < .0001, OR per year of 1.17) and CV history (P = .02, OR for a positive CV history of 3.83) were identified as independent determinants of AC.

CONCLUSIONS:

In this cohort of patients with CKD, we found that patients with aortic calcifications (ACs) had higher sclerostin levels. However, in multivariate analysis, the association became inverse. Additional clinical and experimental studies are urgently required to clarify whether or not sclerostin protects against progression of vascular calcification.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças da Aorta / Proteínas Morfogenéticas Ósseas / Insuficiência Renal Crônica / Proteínas Wnt / Calcificação Vascular Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Endocrinol Metab Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças da Aorta / Proteínas Morfogenéticas Ósseas / Insuficiência Renal Crônica / Proteínas Wnt / Calcificação Vascular Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Endocrinol Metab Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Bélgica